Abstract
The prevalence of chronic liver disease is increasing in the elderly. More than two-thirds of all patients with liver disease in the Western world are due to alcohol liver disease (ALD) and hepatitis C virus occurring alone or in combination. Viral infections are the commonest cause of chronic liver disease which includes alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, drug-induced hepatitis and metabolic diseases such as alpha-antitrypsin deficiency. There is no age-related liver diseases, but the clinical course in the elderly differs in several aspects from those of younger adults. NAFLD is one of the most common liver disorders seen by the primary care physician. Autoimmune hepatitis occurs uncommonly in the elderly; nevertheless there have been several studies in the elderly. Drug-induced liver injury embraces a spectrum of clinical disease ranging from asymptomatic, liver test abnormalities to acute liver failure and to a lesser extent chronicity. Primary biliary cirrhosis is now recognised more frequently than previously because of the increased awareness of the condition and the availability of diagnostic tools leading to earlier diagnosis. Provided hereditary haemochromatosis is detected early and treated, the life expectancy can be normal before cirrhosis occurs.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Frith J, Jones D, Newton Jl. The prevalence of chronic liver disease is increasing in the elderly. Age Aging. 2009; 38(1):11–18.
British Society of Gastroenterology. Care of patients with gastrointestinal disorders in the United Kingdom. An evidenced based strategy for the future. London. British Society of Gastroenterology. March 2005.
Walsh K, Alexander G. Alcoholic liver disease. Postgrad Med J. 2000;76: 280–6.
Office for National Statistics: Health Service Quarterly, Winter. 2008;No:40 p 59–60.
Brave A, Khan R, Marsano L, Ravindra KV, McClaine C. Treatment of alcoholic liver disease Ann Hepatol. 2008;7(1):5–15.
Mueller S, Millonig G, Seitz HK, Alcoholic liver disease and hepatitis C: a frequently understood combination. World Gastrenterol. 2009;15(28):3462–71.
The Hepatitis C Trust and the University of Southampton, Losing the fight against hepatitis C, London 2005.
Floreani A. Liver damage in the elderly with an update. Dig Dis. 2007;25(2):138–43.
British Liver Trust, 2014. http://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease/retreived 23 September 2014.
Teli MR, Day CP, Burt AD. Determinants of progression to cirrhosis or fibrosis in pure alcohol fatty liver. Lancet. 1995; 346:1562–3.
Corrao G, Arico S, Zambon A, Torchio P, Aricos S, Lavecchia C, et al. Is alcohol a risk factor for liver cirrhosis in HBsAg and antiHCV negative subjects. Collective group for the study of liver disease in Italy. J Hepatol. 1997; 27:470–6.
Bellantai S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al, Drinking habits as cofactors of risk for induced liver damage. The Dionysos Study Group. Gut. 1997;41:845–50.
Mihas AA, Hung PD, Hueman DM. Alcoholic hepatitis. e-medicine. updated June 30,2008.
Nagaratnam N, Peiris DC. Acute alcoholic hepatitis in Ceylon. Cey Med J 1971; 21: 28–38.
Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol. 2011;8(9): 491–501.
James OTW. Parenchymal liver disease in the elderly. Gut. 1997;41:430–432.
Pinzani M, Roselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011; 25(2):281–90.
Scholmerich J, Holstege A. Aetiology and pathophysiology of chronic liver disorders. Drugs. 1990;40 suppl 3: 3–22.
Gramenzi A, Caputo F, Baselli M, Kuria F, Loggi E, Andreone P, et al. review article: Alcoholic liver disease: pathophysiological aspects and risk factors. Aliment Pharmocol Ther. 2006; 24:1151–1161.
Galambos JT. Natural history of alcoholic hepatitis 3. Histological changes. Gastroenterol. 1972; 63:1026–35.
Zhang FK, Zhang JV, Jia JD. Treatment of patients with alcoholic liver disease. Hepatbiliary Pancreat Dis Int. 2005;4(1):72–7.
Frazier TH, Stocker AM, Kershner NK, Marsno LS, McClain CJ. Treatment of alcoholic liver disease. Ther Adv Gastroenterol. 2011;4(1):63–81.
Frezza M, di Padova C, Pozzato G, Terpin M, Barona E, Lieb WCS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. NEJM. 1990; 322:95–99.
Day CP. Treatment of alcoholic liver disease. Liver Transpl. 2007; 13(11 Suppl 2):S69–75.
Hoofnagle JH, Kresina T, Fuller RK, Lake JR, Lucey MD, Sorrel MF, et al. Liver transplantation for a LD: executive statement and summary of recommendations-summary of a National Institutes of Health workshop held December 6–7, 1966, Bethesda, Maryland. Liver Transpl Surg. 1997; 3:347–50.
Bergquest CJ, Skoien R, Horsfall, Clouston AD, Jonsson JR, Powell EE. Awareness and experiences of non-alcoholic fatty liver disease by hospital patients in France. J Hepatol. 2012; 57:376–383.
Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006; 40(suppl-1):S5–10.
Raszeja-Wyszomirska J, Lawniczal M, Marlisz W, Miczynska-Kurtez J, Milkiewicz P. Non-alcoholic fatty liver disease –new review. Pol Merkur Lekarski. 2008;24(144):568–71.
Farrell GC, Larker CZ. Non-alcoholic fatty liver disease from steatosis to cirrhosis. Hepatology. 2006;43(2supp 11):S99–S112.
Yu AS, Keeffe ED. Non-alcoholic fatty liver disease. Rev Gastroenterol Disord. 2002;2(1):11–9.
Koehler EM, Schonten JN, Hansen BE, van Roolj FJ, Hofman A, Strickler BH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam Study. H Hepatol. 2012;15(6):1305–11.
Frith J, Day CO, Alstair AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55:6–7–615.
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW, et al. The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.
Adams LA, Talwahar JA. Diagnostic evaluation of non-alcoholic fatty liver disease. J Clin Gastroenterol. 2006;40 sup 1: S34–6.
Clouston AD, Powell EE. Nonalcoholic fatty liver disease: is all the fat bad?. Int Med J. 2004;34:187–191.
Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Can J Gastroenterol. 2002;17(1):38–42.
Arrospide MT. Non-alcoholic fatty liver disease. Rev Gastroenterol Peru. 2013;23(1):49–57.
Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OFW. Autoimmune hepatitis in older patients. Age Ageing. 1997; 21:441–444.
Selby CD, Toghill PJ. Chronic active hepatitis in the elderly. Age Ageing. 1986; 15:350–56.
Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96(5):1587–91.
Parker DR, Kingham JGC. Type1 auto-immune hepatitis in patients in later life. Q J Med 1997; 90:289–296.
Al-Chalabi T, Boccato S, Portmann DC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: A systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45(4):575–583.
Zeniya M, Takahashi H. Characteristics of autoimmune hepatitis in the Asia-pacific region, historical review. Hepatol Internat. 2012; 6(1):342–349.
Berg PA, Klein R. Autoimmune hepatitis and overlap syndromes: diagnosis. Praxis (Bern 199). 2002;91(34):1339–46.
Final Diagnosis-Autoimmune hepatitis, Type 1. http://path.upmc.edu/cases/cause 554/dx.html
Wolf DC, Raghuraman UV. Autoimmune hepatitis. e-medicine update July 24, 2007.
Nagaratnam N, Ambepitiya G, Rajaratnam RG. Lupoid hepatitis, Rendu-Osler-Weber syndrome, clubbing, cyanosis and hypertrophic osteoarthropathy. J Med. 1975; 3&4:291–301.
Fallatah HI, Akbar HO. Autoimmune hepatitis as a unique form of an autoimmune liver disease: Immunological aspects and clinical overview. Autoimmune diseases. vol 2012(2012) Article ID 312517,17pr https://doi.org/10.1155/2012/312817.
Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000;32(1):181–97.
Johnson PJ, Mcfarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998–1005.
Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol. 2011;57(2):213–29.
Bell LN, Chalasani N. Epidemiology of idiosyncratic drug induced liver injury. Semin Liver Dis. 2009;29(4):337–347.
Nourjah P, Ahmad SR, Karwoski C, Willy T. Estimation of acetaminophen (paracetamol) associated overdoses in the United States. Pharmacoepdemiol Dry Sap. 2006; 15 (6):398–405.
Rowden AK, Norvall J, Eldridge Dl, Kirk MA. Updates on acetaminophen toxicity. Med Clin Nth Am 2005;89(6):1145–1159.
Idilman R, Bektas M, Cinar K. The characteristics and clinical outcome of drug induced liver injury: a single center experience. J Clin Gastroenterol. 2010; 44 (6):128–32.
Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007; 6 (6): 673–84 .
Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007; 30(4):277–94.
Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol. 2010; 26 (3):222–226.
Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 Suppl 2:S44–8.
Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Paclkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology. 2006; 44 (6):1581–8.
Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412–22.
Verma S, Kaplowitz N. Diagnosis, management and prevention of drug- induced liver injury. Gut 2009; 58 (11):1555–64.
Mehta N, Ozick L, Gbadehan E. Drug induced hepatitis. e-medicine. updated 28, 2008.
Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis. 2008.;23:3:1 https://doi.org/10.1186/1756-1179-3-1.
Talwalkar JA, Lindor K. Primary biliary cirrhosis. Lancet. 2003;362:53–61.
Hohenester S, Oude-Elferink RP, Beuer S. Primary biliary cirrhosis. Semin immunopathol. 2009;31(3):283–307.
Kulper EM, den Ouden-Muller JW, van Buurin HK. Primary biliary cirrhosis Ned Tijdschr Geneeski. 2009;153:A483.
Chon CY, Park JY. Primary biliary cirrhosis. Korean J Hepatol. 2006; 12(3):364–72.
Kaplan MM, Gershwin ME. Primary biliary cirrhosis. NEJM. 2005;353:1261–1273.
Nishio A, Keeffe EB, Ishibashi H, Gershwin ER. Diagnosis and treatment of primary biliary cirrhosis. Med Sci Monit. 2000; 6(1): 181–93.
McClune CA, Al-Jader LN, May A, Hayes SL, Jackson HA, Worwood M. Hereditary haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet. 2002;111:538–543.
Hanson EH, Imperatore G, Burke W. HFE Gene and hereditary hemochromatosis: A HuGE review’. Am J Epidemol 2001;154(3):193–206.
Bacon BR, Powell LW, Adams PC, Kersina TT, Hofnagle JK. Molecular medicine and haemochromatosis: at the cross roads. Gastroenterology. 1999;116:193–207.
Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4:183–98.
Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Ann Rev Nutr. 2006;26:323–42.
Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anaemia in the 21st century. Therap Adv Gastroenterol. 2011;4(3):177–184.
Burke WD, Thomson E, Khoury MJ, McDonell SM, Press N, Adams PC, et al Hereditary haemochromatosis: gene discovery and its implications for population-based screening. J Am Med Assoc.1998;280:172–78.
Hickman PE, Hourigan LF, Powell LW, Cordingley F, Dimeski G, Ormiston B, et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol. 2003;98:442–7.
Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, Schoniger-Hikela M, et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol.2003;98:442–7.
Tajera K, Shimizu Y, Liver pathology and liver diseases in the elderly. World J Gastroenterol. 2013; 19(4):8459–8467.
Bruguera M. Liver disease in the elderly. Gastroenterologica y Hepatologia 2014;37(9):535–543.
Guttelling JJ, de Man RA, Busschbach JJV, Darlington ASE. Overview of research on health-related quality of life in patients with chronic liver disease. J Med. 2007;65(7):227–231.
Orr JG, Homer T, Tement L, Newton J, McNeil CJ, Hudson M, et al. Heath related quality of life in people with advanced chronic liver disease. J Hepatol. 2014;61(5): 1158–1165.
Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001; 96(7):2199–205.
Bownik H, Saab S. Health-related quality of life after liver transplantation for adult recipients. Liver Trans. 2009;15:S42–S49.
Bianich G, Marcesini G, Nicolino F, Grazian R, Sgarbi D, Lognercio C, et al. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis. 2005; 37(8): 593–600.
Rakoski MO, McCammon RJ, Piette JD, Iwashyna TJ, Marrero JA. Lok AS, et al. Burden of cirrhosis in older Americans and their families: Analysis of the health and retirement study. Hepatology. 2012;55(1):184–191.
Compare Health Funds. Elderly cirrhosis patients strain health system. http://www.medicaldaily.com/elderly-cirrhosis-patients-strain-health-system-239429. Accessed on 19 November 2015.
Kolus K. Study: Elderly with cirrhosis present growing burden on the health care system. Long-Term Living.2002. http://www.Lt/mmagazine.com/news-item/study-elderly-cirrhosis-present-growing-burdenonhealthcaresystem. Accessed on 9 November 2015.
Hsu P, Krajden M, Yoshida EM, Anderson FH, Tomlinson GA, Krahn MD. Does cirrhosis affect quality of life in hepatic cirrhosis impaired patients. Liver Ont 2009. https://doi.org/10.1111/j.1478-3231.2008.01865.x
Dan AA, Kallman JB, Srivastava R, Younosazai Z, Kino A, Younossi ZM,. Impact of chronic liver disease and cirrhosis on health uptake using SF-6D and health utility index. Liver Transplnt. 2008;14(3):321–6.
Ebeid SM, Ah SH, Kamel HY, Elbaz AA, El-Herire HM. Impact of post hepatitis C, chronic liver disease and hepatocellular carcinoma on health related quality of life. Advances on ageing Res https://doi.org/10.4236/aar.2013.46019.
Gan L, Chittni S, Farrell GC. Mechanisms and implications of age related changes in the liver: Non-alcoholic fatty liver disease in the elderly. Curr Gerontol Geriatr Res. https://doi.org/10.1155/2011/8311536.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2018). Chronic Liver Disease. In: Geriatric Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-33434-9_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-33434-9_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33433-2
Online ISBN: 978-3-319-33434-9
eBook Packages: MedicineReference Module Medicine